JPS6379838A - フォスフォジエステラーゼ抑制剤とトロンボキサンａ２拮抗剤とを含む新規な薬剤組成物並びにその用途及び製造法 - Google Patents

フォスフォジエステラーゼ抑制剤とトロンボキサンａ２拮抗剤とを含む新規な薬剤組成物並びにその用途及び製造法

Info

Publication number
JPS6379838A
JPS6379838A JP62228239A JP22823987A JPS6379838A JP S6379838 A JPS6379838 A JP S6379838A JP 62228239 A JP62228239 A JP 62228239A JP 22823987 A JP22823987 A JP 22823987A JP S6379838 A JPS6379838 A JP S6379838A
Authority
JP
Japan
Prior art keywords
thromboxane
antagonist
ethyl
phosphodiesterase inhibitor
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP62228239A
Other languages
English (en)
Japanese (ja)
Inventor
ヴァルター　ハールマン
ヨゼフ　ニックル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Dr Karl Thomae GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Karl Thomae GmbH filed Critical Dr Karl Thomae GmbH
Publication of JPS6379838A publication Critical patent/JPS6379838A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP62228239A 1986-09-13 1987-09-11 フォスフォジエステラーゼ抑制剤とトロンボキサンａ２拮抗剤とを含む新規な薬剤組成物並びにその用途及び製造法 Pending JPS6379838A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3631294.0 1986-09-13
DE19863631294 DE3631294A1 (de) 1986-09-13 1986-09-13 Neue synergistische kombination bestehend aus einem phosphodiesterase-hemmer und einem thromboxan-a(pfeil abwaerts)2(pfeil abwaerts)-antagonisten und deren verwendung bzw. herstellung

Publications (1)

Publication Number Publication Date
JPS6379838A true JPS6379838A (ja) 1988-04-09

Family

ID=6309586

Family Applications (1)

Application Number Title Priority Date Filing Date
JP62228239A Pending JPS6379838A (ja) 1986-09-13 1987-09-11 フォスフォジエステラーゼ抑制剤とトロンボキサンａ２拮抗剤とを含む新規な薬剤組成物並びにその用途及び製造法

Country Status (12)

Country Link
EP (1) EP0260527B1 (enExample)
JP (1) JPS6379838A (enExample)
KR (1) KR880003624A (enExample)
AU (1) AU597718B2 (enExample)
DE (2) DE3631294A1 (enExample)
DK (1) DK472487A (enExample)
ES (1) ES2033755T3 (enExample)
GR (1) GR3004969T3 (enExample)
IL (1) IL83872A0 (enExample)
NZ (1) NZ221779A (enExample)
PH (1) PH23553A (enExample)
ZA (1) ZA876806B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0306846A3 (de) * 1987-09-11 1990-05-02 Dr. Karl Thomae GmbH Neue synergistische Kombination bestehend aus einem Phosphodiesterase-Hemmer und einem Thromboxan-A2-Antagonisten und deren Verwendung bzw. Herstellung
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
AU7604400A (en) 1999-09-21 2001-04-24 Emory University Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4291368A (en) * 1979-03-30 1981-09-22 Borg-Warner Corporation Pulse-width modulated inverter system and method
DE3166627D1 (en) * 1980-12-12 1984-11-15 Thomae Gmbh Dr K Pyrimidones, their preparation and medicines containing them
DE3049207A1 (de) * 1980-12-27 1982-07-29 Dr. Karl Thomae Gmbh, 7950 Biberach Neue trisubstituierte pyrimido (5,4-d) pyrimidine, ihre herstellung und ihre verwendung als arzneimittel
US4568676A (en) * 1983-11-25 1986-02-04 Thomas Jefferson University Method of inhibiting aggregation using thromboxane synthetase inhibitor in combination with a cyclic AMP phosphodiesterase inhibitor

Also Published As

Publication number Publication date
PH23553A (en) 1989-08-25
EP0260527A3 (en) 1989-08-09
DE3631294A1 (de) 1988-03-24
ZA876806B (en) 1989-05-30
DK472487D0 (da) 1987-09-10
EP0260527A2 (de) 1988-03-23
DK472487A (da) 1988-03-14
GR3004969T3 (enExample) 1993-04-28
ES2033755T3 (es) 1993-04-01
AU7829687A (en) 1988-03-17
IL83872A0 (en) 1988-02-29
AU597718B2 (en) 1990-06-07
NZ221779A (en) 1990-03-27
KR880003624A (ko) 1988-05-28
EP0260527B1 (de) 1992-04-01
DE3777926D1 (de) 1992-05-07

Similar Documents

Publication Publication Date Title
KR100738861B1 (ko) 베타-카르볼린 약학 조성물
FI92904B (fi) Menetelmä suun kautta annettavaksi tarkoitetun, aktiiviyhdistettä kontrolloidusti vapauttavan farmaseuttisen formulaation valmistamiseksi
DK170922B1 (da) Cefaclorformulering med langvarig virkning
HU226595B1 (en) Modified release multiple-units dosage composition
HK1044277A (en) Pharmaceutical formulation comprising a beta-carboline and its use for treating sexual dysfunction
NZ205894A (en) Pharmaceutical compositions containing mopidamol(2,6-bis(diethanolamino)-4-piperidino-pyrimido(5,4-d)pyrimidine)
JP2000511170A (ja) 医薬組成物
HK14494A (en) Medicaments containing dipyridamol or mopidamol and o-acetylsalicylic acid, or its physiologically compatible salts, process for their manufacture and their use in combating the formation of thrombus
JP2003510346A (ja) 新規医薬組成物
NZ202140A (en) Delayed release nitrofurantoin tablets
US3459850A (en) Sustained-release tablets,a process and a composition for their preparation
JPH01100118A (ja) ホスホジエステラーゼ阻害剤及びトロンボキサンａ↓２拮抗剤を含む新規な医薬組成物、その使用及びその製造法
PL192648B1 (pl) Preparat farmaceutyczny o kontrolowanym uwalnianiu, zawierający inhibitor ACE jako substancję aktywną
CN109414423A (zh) 包含丙戊酸的延迟释放药物制剂和其用途
US4180559A (en) Coated 1-(2-chlorodibenzo[b,f]oxepin-10-yl)-4-methylpiperazine compositions
JP2001522882A (ja) ザファルカストを含有する医薬品組成物
JPS6379838A (ja) フォスフォジエステラーゼ抑制剤とトロンボキサンａ２拮抗剤とを含む新規な薬剤組成物並びにその用途及び製造法
BG64766B1 (bg) Стабилни състави, съдържащи левосимендан и алгинова киселина
RU2145222C1 (ru) Фармацевтическая композиция, обладающая антигистаминным действием
AT393962B (de) Synergistische arzneimittelkombination mit einem gehalt an einem phosphodiesterase-hemmer und derenverwendung
EP0219737B1 (de) Kombinationspräparat
US6129932A (en) Compositions for inhibiting platelet aggregation
JPH0466846B2 (enExample)
RU2478389C2 (ru) Фармацевтическая противотуберкулезная комбинированная композиция
KR20080017443A (ko) 미분화（4-클로로페닐）［4-（4-피리딜메틸）프탈라진-1-일］ 및이의 염의 즉각-방출형 고-약물-로드 제약 제제